For research purposes only. Not for human consumption. Not medical advice.

Retatrutide

Price updated daily

Weight Loss & Metabolic Health

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 clinical trials have shown unprecedented weight loss results, with some participants losing over 24% of body weight. It represents the next frontier in pharmacological obesity treatment.

Research Use Cases

Maximal pharmacological weight loss
Metabolic syndrome research
Obesity treatment research
Lipid profile improvement

Note: Still in clinical trials. Not yet approved. Research chemical only.